The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.

doi:10.1093/jnci/djaa061

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.

Journal of the National Cancer Institute - 4 Jan 2021

Conley Barbara A, Staudt Lou, Takebe Naoko, Wheeler David A, Wang Linghua, Cardenas Maria F, Korchina Viktoriya, Zenklusen Jean Claude, McShane Lisa M, Tricoli James V, Williams Paul M, Lubensky Irina, O'Sullivan-Coyne Geraldine, Kohn Elise, Little Richard F, White Jeffrey, Malik Shakun, Harris Lyndsay N, Mann Bhupinder, Weil Carol, Tarnuzzer Roy, Karlovich Chris, Rodgers Brian, Shankar Lalitha, Jacobs Paula M, Nolan Tracy, Berryman Sean M, Gastier-Foster Julie, Bowen Jay, Leraas Kristen, Shen Hui, Laird Peter W, Esteller Manel, Miller Vincent, Johnson Adrienne, Edmondson Elijah F, Giordano Thomas J, Kim Benjamin, Ivy S Percy

Abstract excerpt

BACKGROUND: Tumor molecular profiling from patients experiencing exceptional responses to systemic therapy may provide insights into cancer biology and improve treatment tailoring. This pilot study evaluates the feasibility of identifying exceptional responders retrospectively, obtaining pre-exceptional response treatment tumor tissues, and analyzing them with state-of-the-art molecular analysis tools to identify...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Exome Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Feasibility Studies

Share to High-Throughput Nucleotide Sequencing

Share to Pilot Projects

Share to Precision Medicine

Share to Sequence Analysis, RNA

Share to Transcriptome

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 32339229
DOI: 10.1093/jnci/djaa061
PMCID: PMC7781457

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.PMID 32339229Read ↗

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.Semantic proximity Read ↗

Molecular Profiling of Exceptional Responders to Cancer Therapy.Semantic proximity Read ↗

What have we learned from exceptional tumour responses?: Review and perspectives.Semantic proximity Read ↗

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer.Semantic proximity Read ↗

Rare Germline Variants in Immune and Drug Target Genes Among Cancer Exceptional RespondersSemantic proximity Read ↗

Genomic landscape of extraordinary responses in metastatic breast cancer.Semantic proximity Read ↗

Transforming Biomarker Development with Exceptional Responders.Semantic proximity Read ↗

Patient-derived urachal cancer organoids for personalized drug screeningSemantic proximity Read ↗

Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinomaSemantic proximity Read ↗

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read ↗

Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancerSemantic proximity Read ↗

Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in YouthSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.